EN DE
Watch Aprogen Healthcare & Games Inc for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Aprogen Healthcare & Games Inc (109960) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Aprogen Healthcare & Games Inc stock KRW 264, price KRW 1,750, that is 84.9% below the price, quality 55 out of 100. Rating: strongly overvalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7109960005

AH Aprogen Healthcare & Games Inc logo Thin data Nov 14, 2026

Aprogen Healthcare & Games Inc

109960 · KQ

Far too expensive (fair value 85% below the price) and falling price, but solid company: meets 1 of 3 rules.

Follow free in the weekly email
Highly profitable · 74.5% net margin (TTM) 
Low debt 
Generates free cash flow 
Quality 55/100 
Mixed Growth (revenue 3y +0.7 %/yr in KRW) 
Mixed vs. peers (5/10) 
Changed on Oct 25: KRW 202.17 → KRW 263.89 
Fair value 263.89 KRW · Strongly overvalued 
Falling price (downtrend) 
Narrow moat 35/100 · thin data
Thin data 
Extreme value
Watch Aprogen Healthcare & Games Inc for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

110,500 KRW 1,595 KRW Fair Value 263.89 KRW May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range 1,595 KRW – 110,500 KRW · fair‑value band 178.12 KRW – 387.84 KRW · the 1,750 KRW price screens above the 263.89 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow Aprogen Healthcare & Games in your weekly email

Every Wednesday you see whether Aprogen Healthcare & Games is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Aprogen Healthcare & Games Inc. engages in the development of medicines using biomedical technology. The company operates through Game Business, Rental Profit, and Pharmaceutical divisions.

Show moreShow less

It offers specialty drugs, such as antibiotics, circulatory system, digestive system, anti-inflammatory, and analgesic drugs.

The company also offers wireless remote lighting monitoring and control system for streetlights/security lamps, and Bluetooth hands-free for vehicles; rents bio equipment; and leases real estate properties.

In addition, it provides mobile games, such as Dragon Raja M, Legend of super heroes, Heroes & Titans, and Flame shadow. The company was formerly known as Locojoy International Corporation. Aprogen Healthcare & Games Inc. was founded in 1998 and is headquartered in Seongnam, South Korea.

Stock analysis

Aprogen Healthcare & Games Inc (109960) currently trades at 1,750 KRW, while our model-based Fair Value estimate is 263.89 KRW, 85% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of 287.27 KRW per share, and 0 of the 7 models we run sit above the 1,750 KRW price.

Bear case: the Asset-Based group reads lowest at 117.00 KRW, and 7 of the 7 models stay below the price. Data coverage for this calculation is low.

Scenario range: 178.12 KRW (bear) to 387.84 KRW (bull), the price of 1,750 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2021: revenue and profit before it include the divested business. Growth is measured afresh from 2021.

Aprogen Healthcare & Games Inc reported revenue of 9.8B KRW in FY2025 versus 8.4B KRW in FY2021, a compound +3.9%/yr. Reported net income was −5.6B KRW in FY2025.

Key figures

Market cap 26.6B KRW (≈ $20.0M) Micro · P/S ratio 2.96 · Net margin 74.5% · Return on equity −2,415% · Return on assets (EBIT) −0.5% (5-year average) · Operating margin −14.4% · Revenue (TTM) 9.0B KRW · Revenue growth (YoY) +0.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).

What moves the price

The share trades about 70% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at −85%, 109960 screens richer than that median.

Fair Value models

Bear 178.12 KRW Fair Value 263.89 KRW Bull 387.84 KRW
Price 1,750 KRW · Downside -84.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 210.42 KRW 331.65 KRW 516.93 KRW 79
Growth DCF 208.65 KRW 317.91 KRW 476.60 KRW 78
5Y Revenue Exit 167.61 KRW 257.00 KRW 374.48 KRW 72
All 7 models by family
DCF Models
FCF DCF 210.42 KRW 331.65 KRW 516.93 KRW 79
5Y Revenue Exit 167.61 KRW 257.00 KRW 374.48 KRW 72
10Y Revenue Exit 178.12 KRW 263.89 KRW 387.84 KRW 66
Multiples
EV/Revenue 111.85 KRW 164.70 KRW 217.55 KRW 53
Asset-Based
NCAV (Graham) 77.22 KRW 117.00 KRW 146.24 KRW 54
Growth DCF
Growth DCF 208.65 KRW 317.91 KRW 476.60 KRW 78
Rev-Margin DCF 167.61 KRW 256.62 KRW 369.36 KRW 72

Open the full fair value analysis →

Quality Score breakdown

Overall quality 55/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 48
Are margins and returns getting better?
Cashflow 95
Do the profits arrive as real cash?
Financial strength 41
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 34
How calm the share price moves, does not count
Price momentum 16
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2021: revenue and profit before it include the divested business. Growth is measured afresh from 2021.
Revenue growth 1 year
−40.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.7%
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.

109960 screens overvalued: fair value 85% below the price. Compare with ST Pharm Co →

Compare Aprogen Healthcare & Games Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 57 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 55 · Above median
Fair Value upside −84.9% · Bottom 25%
Profitability
Return on assets −1.7% · Bottom 25%
Net margin (12 months) 74.5% · Top 25%
Operating margin (12 months) −14.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 0.9% · Below median

Valuation Multiplesvs Pharmaceuticals median · lower = cheaper

P/B 0.09× · Cheapest 25%
P/S (12 months) 2.96× · Pricier than median
Price / free cash flow (fiscal year) 11.0× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 9
FUTURE (revenue growth)5 · sector 68
PAST (return on equity)0 · sector 23
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 27

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Huons Global Co 084110 19,530 KRW 47,019 KRW +141% vs 109960
DongKook Pharmaceutical Co 086450 26,700 KRW 28,372 KRW +6% vs 109960
ST Pharm Co 237690 75,000 KRW 61,182 KRW −18% vs 109960
Vivozon Pharmaceutical Co 082800 2,800 KRW 2,179 KRW −22% vs 109960
Oscotec Inc 039200 32,400 KRW 21,262 KRW −34% vs 109960
NatureCell Co 007390 21,300 KRW 11,176 KRW −48% vs 109960
Mezzion Pharma Co 140410 61,700 KRW 31,450 KRW −49% vs 109960
BINEX Co 053030 7,010 KRW 1,844 KRW −74% vs 109960
Caregen Co 214370 28,050 KRW 5,414 KRW −81% vs 109960
SHUKRAPHAR SHUKRAPHAR ₹82.22 ₹9.14 −89% vs 109960

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Aprogen Healthcare & Games Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Aprogen Healthcare & Games Inc Fair Value". https://www.fairvalue-calculator.com/stock/109960

Frequently asked questions

Is Aprogen Healthcare & Games Inc (109960) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of 263.89 KRW versus a price of 1,750 KRW, about 85% lower (overvalued).
What is the fair value of 109960?
Our model-based fair value for Aprogen Healthcare & Games Inc is 263.89 KRW (as of Nov 14, 2026), built from audited fundamentals. The current price: 1,750 KRW.
What is the quality score of 109960?
Aprogen Healthcare & Games Inc has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aprogen Healthcare & Games Inc (109960)?
We do not set a price target; the yardstick is the fair value of 263.89 KRW (as of Nov 14, 2026) from 7 valuation models. Cautious scenario 178.12 KRW, optimistic scenario 387.84 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Aprogen Healthcare & Games Inc stock forecast for 2026?
Our models put fair value at 263.89 KRW, about 85% lower versus a price of 1,750 KRW (overvalued). Cautious scenario 178.12 KRW, optimistic scenario 387.84 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Aprogen Healthcare & Games Inc (109960)?
Aprogen Healthcare & Games Inc reported trailing-twelve-month revenue of about 9.0B KRW (latest available figure, as of Nov 14, 2026).
What growth is priced into Aprogen Healthcare & Games Inc (109960)?
Today's price is already fair in a discounted-cash-flow model if free cash flow at Aprogen Healthcare & Games Inc shrinks by more than 40 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue fell 1.0 % per year. As of Nov 14, 2026.
What discount rate (WACC) does the fair value of 109960 use?
Our models discount Aprogen Healthcare & Games Inc at 10.5 %: a base by market capitalisation (nano), damped by beta 1.14, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Aprogen Healthcare & Games Inc that is less than minus 40 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has Aprogen Healthcare & Games Inc (109960) delivered so far?
Over the past 5 years revenue at Aprogen Healthcare & Games Inc shrank 1.0 % a year. The price currently implies free-cash-flow growth of less than minus 40 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Aprogen Healthcare & Games Inc (109960) growing?
The median revenue growth in the sector is +12.1 % a year. That is the yardstick for the growth priced into Aprogen Healthcare & Games Inc (less than minus 40 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Aprogen Healthcare & Games Inc (109960)?
The free-cash-flow yield on the price is 12.54 %: that much free cash flow Aprogen Healthcare & Games Inc produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Aprogen Healthcare & Games Inc (109960)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aprogen Healthcare & Games Inc it is 263.89 KRW per share (as of Nov 14, 2026), against a price of 1,750 KRW. It is the blended result of 7 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Aprogen Healthcare & Games Inc stock overvalued or undervalued in 2026?
As of Nov 14, 2026, 109960 trades above its calculated fair value: price 1,750 KRW, fair value 263.89 KRW, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 109960?
No. The price is what the market pays today (1,750 KRW); the fair value is what the company's own numbers justify (263.89 KRW). For Aprogen Healthcare & Games Inc the two are 1,486 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Aprogen Healthcare & Games Inc worth?
The market values Aprogen Healthcare & Games Inc at about 26.6B KRW (market capitalisation, as of Nov 14, 2026). Per share that is 1,750 KRW; our models calculate a fair value of 263.89 KRW per share.
What do the bullish and bearish scenarios say about 109960?
Our models span a range for Aprogen Healthcare & Games Inc: cautious scenario 178.12 KRW, base 263.89 KRW, optimistic 387.84 KRW per share (as of Nov 14, 2026, price 1,750 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 109960 from its 52-week high?
Aprogen Healthcare & Games Inc trades at 1,750 KRW, about 70% below its 52-week high of 5,800 KRW and 10% above the low of 1,595 KRW (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of 263.89 KRW is for.
Which stocks are comparable to Aprogen Healthcare & Games Inc?
From the same area (Healthcare) we also value ST Pharm Co, Caregen Co, Mezzion Pharma Co, NatureCell Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aprogen Healthcare & Games Inc stock attractive at the current price?
The data as of Nov 14, 2026: price 1,750 KRW, calculated fair value 263.89 KRW (−85%), Quality Score 55/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 109960 calculated?
We run Aprogen Healthcare & Games Inc through 7 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of 263.89 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Aprogen Healthcare & Games Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aprogen Healthcare & Games Inc (109960)?
The closing price on Nov 19, 2026 was 1,750 KRW. Our model-based fair value is 263.89 KRW, about 85% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aprogen Healthcare & Games Inc right now?
The price sits above even our optimistic bull case (387.84 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (178.12 KRW to 387.84 KRW) leaves room in how you read the outcome.

Key figures of Aprogen Healthcare & Games Inc

How large is the market capitalisation of Aprogen Healthcare & Games Inc (109960)?
The market capitalisation of Aprogen Healthcare & Games Inc is 26.6B KRW (≈ $20.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Aprogen Healthcare & Games Inc (109960)?
The price-to-sales ratio of Aprogen Healthcare & Games Inc is 2.96 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Aprogen Healthcare & Games Inc (109960)?
The net margin of Aprogen Healthcare & Games Inc is 74.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Aprogen Healthcare & Games Inc (109960)?
The return on equity (ROE) of Aprogen Healthcare & Games Inc is −2,415% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aprogen Healthcare & Games Inc (109960)?
On an EBIT basis the return on assets of Aprogen Healthcare & Games Inc is −0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aprogen Healthcare & Games Inc (109960)?
The operating margin of Aprogen Healthcare & Games Inc is −14.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aprogen Healthcare & Games Inc (109960)?
Revenue at Aprogen Healthcare & Games Inc is growing 0.9% versus a year earlier (3y avg +0.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Aprogen Healthcare & Games Inc (109960)?
Earnings per share at Aprogen Healthcare & Games Inc are growing 900% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Aprogen Healthcare & Games Inc (109960) carry?
The net debt of Aprogen Healthcare & Games Inc is 2.0B KRW (fiscal year 2025, ≈ 0.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Aprogen Healthcare & Games Inc in the live analysis

One click puts Aprogen Healthcare & Games Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.